Beclometasone/formoterol/glycopyrrolate

Drug Profile

Beclometasone/formoterol/glycopyrrolate

Alternative Names: BDP/FF/GB; Beclometasone dipropionate/formoterol fumarate/glycopyrrolate bromide; Beclometasone/glycopyrrolate/formoterol; CHF 5993 pMDI; CHF-5993

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Jan 2017 Chiesi Farmaceutici completes the phase III Tristar trial in Chronic obstructive pulmonary disease in Lithuania, Sweden, United Kingdom, Netherlands, Hungary, Germany, Belgium and Poland (Inhalation) (EudraCT2014-001487-35)
  • 01 Nov 2016 Chiesi Farmaceutici plans a phase I trial for Asthma and Chronic obstructive pulmonary disease in United Kingdom (Inhalation) (NCT02975843)
  • 01 Jul 2016 Chiesi Farmaceutici completes a phase I pharmacokinetics trial in Healthy volunteers in Belgium (Inhalation) (NCT02743013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top